Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF LEGAL OFFICER | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,929 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 5,034 · Balance 52,644 Row 2 · 2026-06-12 · Tax withholding · Disposed 2,715 · Balance 49,929 F1: The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,068 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 5,034 · Balance 10,068 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,034 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000077 · wk-form4_1781554184.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,068 Underlying: Common Stock · 5,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,715 | $69.50 | $188,692.50 |
DisclosureSEC source: 0001159036-26-000077 · wk-form4_1781554184.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,929 F1 · shares: The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000077 · wk-form4_1781554184.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,011 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000030 · wk-form4_1771974966.xml · derivative · entry 6 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,022 Underlying: Common Stock · 7,011 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,782 | $70.64 | $267,160.48 |
DisclosureSEC source: 0001159036-26-000030 · wk-form4_1771974966.xml · nonDerivative · entry 4 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,610 F2 · shares: The reported disposition of 3,782 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000030 · wk-form4_1771974966.xml · nonDerivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000030 · wk-form4_1771974966.xml · derivative · entry 5 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,995 Underlying: Common Stock · 5,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,876 | $70.98 | $204,138.48 |
DisclosureSEC source: 0001159036-26-000030 · wk-form4_1771974966.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,381 F1 · shares: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000030 · wk-form4_1771974966.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 12,016 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000027 · wk-form4_1771372424.xml · derivative · entry 6 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,796 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000027 · wk-form4_1771372424.xml · derivative · entry 5 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,796 Underlying: Common Stock · 4,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 6,481 | $79.44 | $514,850.64 |
DisclosureSEC source: 0001159036-26-000027 · wk-form4_1771372424.xml · nonDerivative · entry 4 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,925 F2 · shares: The reported disposition of 6,481 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 12,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000027 · wk-form4_1771372424.xml · nonDerivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,587 | $79.44 | $205,511.28 |
DisclosureSEC source: 0001159036-26-000027 · wk-form4_1771372424.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,390 F1 · shares: The reported disposition of 2,587 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000027 · wk-form4_1771372424.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 29,502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000016 · wk-form4_1770862856.xml · derivative · entry 5 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,502 Underlying: Common Stock · 29,502 shares Expires not disclosed F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 7,808 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000016 · wk-form4_1770862856.xml · derivative · entry 4 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,127 Underlying: Common Stock · 7,808 shares Expires not disclosed F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 4,651 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000016 · wk-form4_1770862856.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,016 Underlying: Common Stock · 4,651 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 17,396 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000016 · wk-form4_1770862856.xml · derivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,396 Underlying: Common Stock · 17,396 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 18,730 | $0.00 Strike: $80.48 | $0.00 |
DisclosureSEC source: 0001159036-26-000016 · wk-form4_1770862856.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,730 Underlying: Common Stock · 18,730 shares Expires 2036-02-09 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,611 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000005 · wk-form4_1767743723.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 4,243 | $70.31 | $298,325.33 |
DisclosureSEC source: 0001159036-26-000005 · wk-form4_1767743723.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,181 F1 · shares: The reported disposition of 4,243 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000005 · wk-form4_1767743723.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 21:33 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,035 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017270 · form4-06132025_090601.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,102 Underlying: Common Stock · 5,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 21:33 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,711 | $54.54 | $147,857.94 |
DisclosureSEC source: 0001415889-25-017270 · form4-06132025_090601.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,813 F1 · shares: The reported disposition of 2,711 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 21:33 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017270 · form4-06132025_090601.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,012 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005306 · form4-02242025_100209.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,033 Underlying: Common Stock · 7,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,775 | $57.75 | $218,006.25 |
DisclosureSEC source: 0001415889-25-005306 · form4-02242025_100209.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,489 F1 · shares: The reported disposition of 3,775 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005306 · form4-02242025_100209.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:50 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 21,327 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005175 · form4-02212025_110225.xml · derivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,327 Underlying: Common Stock · 21,327 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:50 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 22,603 | $0.00 Strike: $57.44 | $0.00 |
DisclosureSEC source: 0001415889-25-005175 · form4-02212025_110225.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,603 Underlying: Common Stock · 22,603 shares Expires 2035-02-20 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,796 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004508 · form4-02182025_110258.xml · derivative · entry 6 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,592 Underlying: Common Stock · 4,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 17,409 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004508 · form4-02182025_110258.xml · derivative · entry 5 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,582 | $58.29 | $150,504.78 |
DisclosureSEC source: 0001415889-25-004508 · form4-02182025_110258.xml · nonDerivative · entry 4 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,252 F2 · shares: The reported disposition of 2,582 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004508 · form4-02182025_110258.xml · nonDerivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 9,373 | $58.29 | $546,352.17 |
DisclosureSEC source: 0001415889-25-004508 · form4-02182025_110258.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,038 F1 · shares: The reported disposition of 9,373 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 17,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004508 · form4-02182025_110258.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 30,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004240 · form4-02142025_110259.xml · derivative · entry 4 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,050 Underlying: Common Stock · 30,050 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Unit · Derivative | 7,269 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004240 · form4-02142025_110259.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,269 Underlying: Common Stock · 7,269 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 4,698 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004240 · form4-02142025_110259.xml · derivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 4,698 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 6,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004240 · form4-02142025_110259.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,409 Underlying: Common Stock · 6,050 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 22:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,611 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000811 · form4-01062025_100155.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,611 Underlying: Common Stock · 7,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 22:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 4,289 | $47.74 | $204,756.86 |
DisclosureSEC source: 0001415889-25-000811 · form4-01062025_100155.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,002 F1 · shares: The reported disposition of 4,289 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 22:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000811 · form4-01062025_100155.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:17 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 20,137 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016891 · form4-06142024_080629.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,137 Underlying: Common Stock · 20,137 shares Expires not disclosed F1 · shares: The grant of restricted stock units reported on this Form 4 was awarded to Mr. Snyder in recognition of his contribution to the recent issuance of a European patent covering the Company's ENHANZE(R) rHuPH20 product that the Company provides to its licensees. F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 28,045 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005542 · form4-02272024_100212.xml · derivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,045 Underlying: Common Stock · 28,045 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 29,064 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001415889-24-005542 · form4-02272024_100212.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,064 Underlying: Common Stock · 29,064 shares Expires 2034-02-23 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,796 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004476 · form4-02202024_110248.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,388 Underlying: Common Stock · 4,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,577 | $36.10 | $93,029.70 |
DisclosureSEC source: 0001415889-24-004476 · form4-02202024_110248.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,680 F1 · shares: The reported disposition of 2,577 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004476 · form4-02202024_110248.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.